16S_NP rRNA_NP Mutation-Mediated_NP Tetracycline_NP Resistance_NP in_IN Helicobacter_NP pylori_NNS Most_RBS Helicobacter_JJ pylori_NNS strains_NNS are_VBP susceptible_JJ to_TO tetracycline_NN ,_, an_DT antibiotic_NN commonly_RB used_VBN for_IN the_DT eradication_NN of_IN H._NP pylori_NNS ._SENT However_RB ,_, an_DT increase_NN in_IN incidence_NN of_IN tetracycline_NN resistance_NN in_IN H._NP pylori_NNS has_VBZ recently_RB been_VBN reported_VBN ._SENT Here_RB the_DT mechanism_NN of_IN tetracycline_NN resistance_NN of_IN the_DT first_JJ Dutch_JJ tetracycline-resistant_NN (_( Tetr_NP )_) H._NP pylori_NNS isolate_NN (_( strain_NN 181_CD )_) is_VBZ investigated_VBN ._SENT Twelve_NP genes_NNS were_VBD selected_VBN from_IN the_DT genome_NN sequences_NNS of_IN H._NP pylori_NNS strains_VBZ 26695_CD and_CC J99_NP as_IN potential_JJ candidate_NN genes_NNS ,_, based_VBN on_IN their_PP$ homology_NN with_IN tetracycline_NN resistance_NN genes_NNS in_IN other_JJ bacteria_NNS ._SENT With_IN the_DT exception_NN of_IN the_DT two_CD 16S_JJ rRNA_NN genes_NNS ,_, none_NN of_IN the_DT other_JJ putative_JJ tetracycline_NN resistance_NN genes_NNS was_VBD able_JJ to_TO transfer_VB tetracycline_NN resistance_NN ._SENT Genetic_JJ transformation_NN of_IN the_DT Tets_NP strain_NN 26695_CD with_IN smaller_JJR overlapping_JJ PCR_NP fragments_NNS of_IN the_DT 16S_JJ rRNA_NN genes_NNS of_IN strain_NN 181_CD ,_, revealed_VBD that_IN a_DT 361-bp_JJ fragment_NN that_WDT spanned_VBD nucleotides_NNS 711_CD to_TO 1071_CD was_VBD sufficient_JJ to_TO transfer_VB resistance_NN ._SENT Sequence_NN analysis_NN of_IN the_DT 16S_JJ rRNA_NN genes_NNS of_IN the_DT Tetr_NP strain_NN 181_CD ,_, the_DT Tets_NP strain_NN 26695_CD ,_, and_CC four_CD Tetr_NP 26695_CD transformants_NNS showed_VBD that_IN a_DT single_JJ triple-base-pair_NN substitution_NN ,_, AGA926-928->TTC_NP ,_, was_VBD present_JJ within_IN this_DT 361-bp_JJ fragment_NN ._SENT This_DT triple-base-pair_NN substitution_NN ,_, present_JJ in_IN both_DT copies_NNS of_IN the_DT 16S_JJ rRNA_NN gene_NN of_IN all_PDT our_PP$ TetrH_NP ._SENT pylori_NNS transformants_NNS ,_, resulted_VBN in_IN an_DT increased_VBN MIC_NN of_IN tetracycline_NN that_WDT was_VBD identical_JJ to_TO that_DT for_IN the_DT Tetr_NP strain_NN 181_CD ._SENT Helicobacter_NN pylori_NNS is_VBZ a_DT spiral-shaped_JJ ,_, gram-negative_JJ bacterium_NN that_WDT causes_VBZ chronic_JJ infections_NNS in_IN the_DT gastric_JJ mucosa_NN ._SENT This_DT infection_NN will_MD persist_VB for_IN life_NN ,_, unless_IN treated_VBN with_IN antibiotics_NNS ._SENT Cure_NN of_IN H._NP pylori_NNS infection_NN results_NNS in_IN ulcer_NN healing_NN and_CC may_MD reduce_VB the_DT risk_NN of_IN gastric_JJ cancer_NN and_CC gastric_JJ lymphoma_NN ._SENT The_DT highest_JJS cure_NN rates_NNS have_VBP been_VBN obtained_VBN with_IN antimicrobial_JJ treatments_NNS that_WDT include_VBP two_CD or_CC more_JJR antimicrobial_JJ drugs_NNS ,_, a_DT bismuth_NN component_NN ,_, and/or_CC a_DT proton_NN pump_NN inhibitor_NN ._SENT For_IN the_DT treatment_NN of_IN H._NP pylori_NNS infections_NNS ,_, tetracycline-based_JJ triple_JJ or_CC quadruple_JJ therapies_NNS are_VBP often_RB used_VBN as_IN a_DT second-line_NN treatment_NN ._SENT Until_IN the_DT end_NN of_IN the_DT last_JJ century_NN only_RB a_DT few_JJ reports_NNS were_VBD published_VBN on_IN spontaneous_JJ tetracycline_NN resistance_NN (_( ;_: P._NP D._NP Midolo_NP ,_, M._NP G._NP Korman_NP ,_, J._NP D._NP Turnidge_NP ,_, and_CC J._NP R._NP Lambert_NP ,_, Letter_NP ,_, Lancet_NP 347:1194-1195_CD ,_, 1996_CD )_) ,_, and_CC it_PP was_VBD generally_RB accepted_VBN that_IN tetracycline_NN resistance_NN (_( MIC_JJ >=_NN 4_CD mug/ml_NN )_) in_IN H._NP pylori_NNS is_VBZ very_RB rare_JJ ._SENT However_RB ,_, in_IN the_DT last_JJ 2_CD years_NNS an_DT increase_NN in_IN the_DT incidence_NN of_IN tetracycline_NN resistance_NN in_IN H._NP pylori_NNS has_VBZ been_VBN reported_VBN ._SENT Tetracycline_NN inhibits_VBZ the_DT protein_NN synthesis_NN by_IN binding_VBG to_TO the_DT 30S_JJ ribosomal_JJ subunit_NN ._SENT In_IN most_JJS bacteria_NNS resistance_NN to_TO tetracycline_NN is_VBZ due_JJ to_TO an_DT energy-dependent_JJ efflux_NN of_IN tetracycline-cation_NN complexes_NNS across_IN the_DT cell_NN membrane_NN by_IN membrane-associated_JJ efflux_NN proteins_NNS ._SENT Export_NN of_IN tetracycline_NN complexes_NNS out_RP of_IN the_DT cell_NN reduces_VBZ the_DT intracellular_JJ drug_NN concentration_NN and_CC protects_VBZ the_DT ribosomes_NNS from_IN tetracycline_NN ._SENT Overexpression_NN of_IN the_DT efflux_NN genes_NNS confers_VBZ tetracycline_NN resistance_NN ,_, while_IN the_DT sensitivity_NN to_TO tetracycline_NN increases_NNS by_IN deletions_NNS in_IN these_DT genes_NNS ._SENT The_DT second_JJ common_JJ mechanism_NN of_IN resistance_NN is_VBZ mediated_VBN through_IN ribosomal_JJ protection_NN proteins_NNS ._SENT These_DT cytoplasmic_JJ proteins_NNS confer_VBP tetracycline_NN resistance_NN either_CC by_IN a_DT reduction_NN of_IN the_DT affinity_NN of_IN ribosomes_NNS for_IN tetracycline_NN or_CC by_IN releasing_VBG the_DT bound_JJ antibiotic_NN from_IN the_DT ribosome_NN ._SENT The_DT ribosomal_JJ protection_NN proteins_NNS ,_, such_JJ as_IN TetM_NP ,_, TetO_NP ,_, and_CC TetS_NP ,_, show_NN homology_NN with_IN the_DT elongation_NN factors_NNS EF-G_NP and_CC EF-Tu_NP ._SENT Beside_IN these_DT two_CD most_RBS common_JJ tetracycline_NN resistance_NN mechanisms_NNS ,_, two_CD other_JJ mechanisms_NNS have_VBP been_VBN described_VBN ._SENT One_PP is_VBZ based_VBN on_IN enzymatic_JJ inactivation_NN of_IN tetracycline_NN by_IN the_DT product_NN of_IN TetX_NP in_IN the_DT presence_NN of_IN oxygen_NN and_CC NADPH_NN ,_, and_CC the_DT other_JJ originates_VBZ from_IN mutations_NNS in_IN the_DT 16S_JJ rRNA_NN genes_NNS that_WDT affect_VBP the_DT binding_JJ site_NN of_IN tetracycline_NN ._SENT TABLE_NN 1_CD |_SYM H._NP pylori_NNS genes_NNS potentially_RB involved_VBN in_IN tetracycline_NN resistance_NN We_PP recently_RB isolated_VBD a_DT tetracycline-resistant_JJ (_( Tetr_NP )_) H._NP pylori_NNS isolate_NN (_( strain_NN 181_CD )_) ,_, from_IN a_DT 72-year-old_JJ male_JJ dyspeptic_JJ patient_NN ._SENT Here_RB we_PP describe_VBP the_DT molecular_JJ mechanism_NN of_IN tetracycline-resistance_NN in_IN this_DT strain_NN ._SENT To_TO achieve_VB this_DT ,_, 12_CD genes_NNS were_VBD selected_VBN from_IN the_DT published_JJ H._NP pylori_NNS genomes_NNS as_IN potential_JJ candidates_NNS ,_, based_VBN on_IN their_PP$ homology_NN with_IN tetracycline_NN resistance_NN genes_NNS in_IN other_JJ bacteria_NNS ._SENT These_DT putative_JJ tetracycline_NN resistance_NN genes_NNS were_VBD amplified_VBN from_IN the_DT genome_NN of_IN the_DT Tetr_NP strain_NN 181_CD and_CC used_VBN for_IN genetic_JJ transformation_NN of_IN the_DT tetracycline-sensitive_JJ (_( Tets_NP )_) strain_VBP 26695_CD in_IN order_NN to_TO identify_VB the_DT changes_NNS responsible_JJ for_IN tetracycline_NN resistance_NN ._SENT Bacterial_JJ strains_NNS and_CC growth_NN conditions_NNS ._SENT |_SYM H._NP pylori_NNS strains_NNS used_VBN in_IN this_DT study_NN were_VBD the_DT Tetr_NP strain_NN 181_CD and_CC the_DT TetsH_NP ._SENT pylori_NNS strains_NNS 26695_CD ,_, J99_NP ,_, SS1_NP ,_, and_CC ATCC_NP 43504_NP (_( American_NP Type_NP Culture_NP Collection_NP )_) ._SENT Bacteria_NNS were_VBD routinely_RB grown_VBN on_IN Columbia_NP agar_NN plates_NNS (_( Becton_NP Dickinson_NP ,_, Cockeysville_NP ,_, Md._NP )_) supplemented_VBD with_IN 7_CD %_NN lysed_VBD horse_NN blood_NN (_( BioTrading_NP ,_, Mijdrecht_NP ,_, The_DT Netherlands_NPS )_) and_CC H._NP pylori_NNS Dent_NP selective_JJ supplement_NN (_( Oxoid_NP ,_, Basingstoke_NP ,_, United_NP Kingdom_NP )_) ,_, referred_VBD to_TO as_IN Dent_NP plates_NNS ._SENT Bacteria_NNS were_VBD inoculated_VBN on_IN these_DT plates_NNS and_CC incubated_VBN for_IN 48_CD to_TO 72_CD h_NN at_IN 37C_JJ in_IN a_DT microaerobic_JJ atmosphere_NN of_IN 5_CD %_NN O2_NP ,_, 10_CD %_NN CO2_NN ,_, and_CC 85_CD %_NN N2_NN ._SENT Bacterial_JJ stocks_NNS were_VBD prepared_VBN by_IN suspending_VBG bacteria_NNS ,_, harvested_VBN from_IN culture_NN plates_NNS with_IN a_DT sterile_JJ cotton_NN swab_NN ,_, in_IN brain_NN heart_NN infusion_NN with_IN 20_CD %_NN glycerol_NN and_CC stored_VBD at_IN -80C_NN ._SENT Determination_NN of_IN MIC_NP ._SENT |_SYM The_DT MIC_NN was_VBD routinely_RB determined_VBN with_IN the_DT E-test_NN (_( AB_NP Biodisk_NP ,_, Solna_NP ,_, Sweden_NP )_) ._SENT Inocula_NNS were_VBD prepared_VBN from_IN a_DT fresh_JJ H._NP pylori_NNS culture_NN grown_VBN routinely_RB for_IN 2_CD days_NNS on_IN Dent_NP plates_NNS ._SENT Columbia_NP agar_NN plates_NNS containing_VBG 7_CD %_NN lysed_VBD horse_NN blood_NN ,_, but_CC no_DT Dent_NP supplement_NN ,_, were_VBD inoculated_VBN with_IN approximately_RB 2_CD x_SYM 108_CD CFU_NP in_IN 20_CD mul_NN of_IN 0.9_CD %_NN NaCl_NP ,_, the_DT plates_NNS were_VBD dried_VBN for_IN 3_CD to_TO 4_CD min_NN ,_, and_CC then_RB the_DT E-test_NN strips_NNS were_VBD applied_VBN to_TO the_DT agar_NN surface_NN ._SENT The_DT plates_NNS were_VBD incubated_VBN at_IN 37C_JJ under_IN microaerobic_JJ conditions_NNS ,_, and_CC 3_CD days_NNS later_RBR the_DT MIC_NN was_VBD determined_VBN by_IN the_DT intercept_NN of_IN the_DT zone_NN of_IN inhibition_NN with_IN the_DT graded_VBN E-test_NN strip_NN ._SENT By_IN this_DT method_NN the_DT susceptibility_NN was_VBD determined_VBN for_IN tetracycline_NN ,_, doxycycline_NN ,_, minocycline_NN ,_, amoxicillin_NP ,_, clarithromycin_NN ,_, and_CC metronidazole_NN ._SENT The_DT isolates_NNS were_VBD considered_VBN resistant_JJ when_WRB the_DT MICs_NN of_IN tetracycline_NN ,_, doxycycline_NN ,_, and_CC minocycline_NN were_VBD >=4_JJ mug/ml_NN and_CC when_WRB those_DT of_IN amoxicillin_NP ,_, clarithromycin_NN ,_, and_CC metronidazole_NN were_VBD >=8_JJ ,_, >=2_JJ ,_, and_CC >=8mug/ml_NN ,_, respectively_RB ._SENT Natural_JJ transformation_NN of_IN H._NP pylori_NNS ._SENT |_SYM Bacteria_NP were_VBD transformed_VBN with_IN similar1_JJ mug_NN of_IN genomic_JJ DNA_NN or_CC similar250_NN ng_NNS of_IN PCR-amplified_JJ gene_NN products_NNS from_IN strain_NN 181_CD ,_, as_RB described_VBN previously_RB ._SENT Tetr_NP transformants_NNS were_VBD selected_VBN on_IN Dent_NP plates_NNS containing_VBG tetracycline_NN (_( 2_CD mug/ml_NN ;_: Sigma_NP Aldrich_NP Chemie_NP ,_, Zwijndrecht_NP ,_, The_DT Netherlands_NPS )_) ._SENT As_IN controls_NNS ,_, bacteria_NNS were_VBD transformed_VBN with_IN either_DT genomic_JJ DNA_NN of_IN the_DT Tetr_NP strain_NN ,_, TE_NNS (_( 1_CD mM_NP Tris-HCl_NP ,_, 0.1_CD mM_NP EDTA_NP [_SYM pH_NN 8.0_CD ]_SYM )_) ,_, or_CC DNA_NN from_IN the_DT Tets_NP strains_NNS 26695_CD ,_, J99_NP ,_, SS1_NP ,_, and_CC ATCC43504_NP ._SENT Individual_JJ bacterial_JJ colonies_NNS present_JJ on_IN tetracycline-containing_JJ plates_NNS (_( 2_CD mug/ml_NN )_) were_VBD selected_VBN ,_, and_CC their_PP$ MICs_NN of_IN tetracycline_NN were_VBD determined_VBN ._SENT PCR_NP ._SENT |_SYM Oligonucleotide_NN primers_NNS (_( Isogen_NP ,_, Maarsen_NP ,_, The_DT Netherlands_NPS )_) used_VBN for_IN PCR_NP amplification_NN were_VBD based_VBN on_IN the_DT genome_NN sequences_NNS of_IN H._NP pylori_NNS strains_VBZ 26695_CD and_CC J99_NP (_( Table_NP ;_: Fig._NN and_CC )_) ._SENT PCR_NP was_VBD performed_VBN in_IN an_DT automated_JJ thermal_JJ cycler_NN (_( I-Cycler_NP ;_: Bio-Rad_NP )_) ,_, in_IN a_DT final_JJ volume_NN of_IN 50_CD mul_NN ,_, using_VBG the_DT PCR-core_JJ system_NN I_PP (_( Promega_NP ,_, Madison_NP ,_, Wis._NP )_) ,_, with_IN approximately_RB 25_CD pg_NN of_IN template_NN genomic_JJ DNA_NN and_CC 25_CD pmol_NN of_IN each_DT primer_NN ._SENT Sequence_NN analysis_NN ._SENT |_SYM Direct_NP sequencing_NP of_IN the_DT obtained_VBN PCR_NP products_NNS was_VBD performed_VBN by_IN Baseclear_NP Inc._NP (_( Leiden_NP ,_, The_DT Netherlands_NPS )_) ._SENT Sequence_NN data_NNS were_VBD analyzed_VBN with_IN the_DT help_NN of_IN Lasergene_NP (_( DNAstar_NP ,_, Madison_NP ,_, Wis._NP )_) ,_, and_CC Sci_NP Ed_NP Central_NP (_( Scientific_NP &_CC Educational_NP Software_NP ,_, Durham_NP ,_, N.C._NP )_) software_NN ._SENT Nucleotide_NN sequence_NN accession_NN number_NN ._SENT |_SYM The_DT 16S_JJ rRNA_NN gene_NN sequence_NN of_IN TetrH_NP ._SENT pylori_NNS strain_VBP 181_NP has_VBZ been_VBN deposited_VBN into_IN to_TO the_DT GenBank_NP sequence_NN database_NN ,_, under_IN accession_NN no_RB ._SENT ._SENT FIG._NN 1_CD ._SENT |_SYM Schematic_NP representation_NN of_IN the_DT 16S_JJ rRNA_NN genes_NNS of_IN H._NP pylori_NNS Schematic_NP representation_NN of_IN the_DT 16S_JJ rRNA_NN genes_NNS of_IN H._NP pylori_NNS ._SENT Alignment_NN of_IN the_DT 16S_JJ rRNA_NN genes_NNS (_( rrnA_NN and_CC rrnB_NN )_) from_IN the_DT Tetr_NP strain_NN 181_CD ,_, the_DT Tets_NP strain_NN 26695_CD ,_, and_CC four_CD Tetr_NP 26695_CD transformants_NNS is_VBZ shown_VBN ._SENT Sequence_NN analysis_NN of_IN the_DT 16S_JJ rRNA_NN genes_NNS revealed_VBD only_RB a_DT few_JJ base_NN pair_NN substitutions_NNS (_( numbering_VBG according_VBG to_TO 16S_JJ rrnA_NN of_IN H._NP pylori_NNS strain_VBP 26695_CD )_) in_IN the_DT Tetr_NP strain_NN 181_CD that_WDT did_VBD not_RB occur_VB in_IN the_DT Tets_NP strain_NN 26695_CD ._SENT For_IN the_DT identification_NN of_IN the_DT 16S_JJ rRNA_NN region_NN required_VBN for_IN tetracycline_NN resistance_NN ,_, the_DT Tets_NP strain_NN 26695_CD was_VBD transformed_VBN with_IN smaller_JJR overlapping_JJ PCR_NP fragments_NNS of_IN the_DT 16S_JJ rRNA_NN gene_NN of_IN the_DT Tetr_NP strain_NN 181_CD (_( only_RB fragments_VBZ containing_VBG mutations_NNS are_VBP shown_VBN )_) ._SENT The_DT transformants_NNS were_VBD selected_VBN on_IN tetracycline_NN (_( 2_CD mug/ml)-containing_JJ Dent_NP plates_NNS ._SENT Primers_NNS used_VBN for_IN the_DT amplification_NN of_IN the_DT smaller_JJR overlapping_JJ PCR_NP fragments_NNS started_VBD at_IN the_DT outside_NN of_IN the_DT fragment_NN and_CC each_DT had_VBD a_DT length_NN of_IN 20_CD bp_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Both_DT 16S_JJ rRNA_NN genes_NNS are_VBP mutated_VBN in_IN H._NP pylori_NNS Both_CC 16S_JJ rRNA_NN genes_NNS are_VBP mutated_VBN in_IN H._NP pylori_NNS tetracycline_NN resistance_NN ._SENT rrnA-_NN and_CC rrnB-specific_JJ sequences_NNS were_VBD amplified_VBN using_VBG specific_JJ primers_NNS based_VBN on_IN sequences_NNS which_WDT are_VBP found_VBN outside_IN the_DT two_CD 16S_JJ rRNA_NN genes_NNS ._SENT The_DT rrnA-specific_JJ primers_NNS ,_, F1_NP and_CC F2_NP ,_, are_VBP located_VBN at_IN position_NN 1207020_CD and_CC 1207242_CD (_( numbers_NNS corresponding_JJ to_TO the_DT H._NP pylori_NNS 26695_CD sequence_NN )_) ,_, respectively_RB ,_, and_CC the_DT rrnB-specific_JJ primers_NNS ,_, F3_NP and_CC F4_NP ,_, are_VBP located_VBN at_IN position_NN 1510569_CD and_CC 1510809_CD ,_, respectively_RB ._SENT For_IN amplification_NN ,_, primer_NN R1_NP (_( located_VBN at_IN position_NN 1208293_CD and_CC 1511828_CD )_) was_VBD used_VBN in_IN combination_NN with_IN one_CD of_IN the_DT other_JJ primers_NNS ._SENT All_DT primers_NNS had_VBD a_DT length_NN of_IN 20_CD bp_NN ._SENT Determination_NN of_IN the_DT MICs_NN of_IN various_JJ antibiotics_NNS ._SENT |_SYM MICs_NP of_IN the_DT four_CD antibiotics_NNS commonly_RB used_VBN in_IN anti-H_NP ._SENT pylori_NNS therapy_NN ,_, as_RB well_RB as_IN those_DT of_IN two_CD antibiotics_NNS that_WDT belong_VBP to_TO the_DT tetracycline_NN family_NN ,_, were_VBD determined_VBN by_IN E-test_NN for_IN the_DT TetrH_NP ._SENT pylori_NNS strain_VBP 181_CD and_CC the_DT H._NP pylori_NNS reference_NN strain_NN 26695_CD ._SENT The_DT MIC_NN of_IN tetracycline_NN for_IN strain_NN 181_CD was_VBD 8_CD mug/ml_NN (_( susceptibility_NN breakpoint_NN >=_NN 4_CD mug/ml_NN )_) ,_, while_IN the_DT MIC_NN for_IN strain_NN 26695_CD was_VBD 0.19_CD mug/ml_NN ._SENT The_DT MICs_NP of_IN the_DT two_CD other_JJ tetracyclines_NNS ,_, doxycycline_NN and_CC minocycline_NN ,_, were_VBD also_RB significantly_RB higher_JJR for_IN strain_NN 181_CD than_IN for_IN strain_NN 26695_CD ._SENT For_IN the_DT three_CD other_JJ routinely_RB used_VBN antibiotics_NNS (_( amoxicillin_NP ,_, clarithromycin_NN ,_, and_CC metronidazole_NN )_) the_DT MICs_NN varied_VBN between_IN <0.016_and TTC_NP ._SENT Both_DT copies_NNS of_IN 16S_JJ rRNA_NN genes_NNS are_VBP involved_VBN in_IN tetracycline_NN resistance_NN ._SENT |_SYM The_DT primers_NNS that_WDT were_VBD originally_RB used_VBN for_IN amplification_NN of_IN the_DT 16S_JJ rRNA_NN genes_NNS did_VBD not_RB distinguish_VB between_IN the_DT two_CD copies_NNS present_JJ on_IN the_DT H._NP pylori_NNS chromosome_NN ._SENT To_TO assess_VB the_DT involvement_NN of_IN each_DT copy_NN of_IN the_DT 16S_JJ rRNA_NN genes_NNS in_IN tetracycline_NN resistance_NN ,_, specific_JJ oligonucleotide_NN primers_NNS were_VBD developed_VBN ._SENT These_DT specific_JJ primers_NNS are_VBP based_VBN on_IN sequences_NNS which_WDT are_VBP located_VBN approximately_RB 350_CD to_TO 600_CD bp_NN outside_IN the_DT both_CC 16S_JJ rRNA_NN genes_NNS ,_, rrnA_NN and_CC rrnB_NN ._SENT This_DT allowed_VBN amplification_NN of_IN rrnA-_NN and_CC rrnB-specific_JJ sequences_NNS ._SENT rrnA-_NN and_CC rrnB-containing_NN PCR-fragments_NNS were_VBD obtained_VBN for_IN the_DT Tetr_NP strain_NN 181_CD ,_, the_DT eight_CD 26695_CD transformants_NNS ,_, and_CC Tets_NP strain_NN 26695_CD ,_, and_CC their_PP$ DNA_NN sequences_NNS were_VBD determined_VBN ._SENT As_IN expected_VBN ,_, the_DT rrnA_NN and_CC rrnB_NN sequences_NNS were_VBD identical_JJ ,_, where_WRB as_RB the_DT sequences_NNS outside_IN the_DT 16S_JJ rRNA_NN genes_NNS were_VBD different_JJ ._SENT While_IN the_DT Tets_NP strain-derived_JJ fragments_NNS contained_VBD the_DT AGA_NP sequence_NN in_IN both_DT genes_NNS ,_, both_CC for_IN strain_NN 181_CD and_CC the_DT eight_CD 26695_CD transformants_NNS ,_, the_DT triple-base-pair_NN substitution_NN AGA926-928->TTC_NP was_VBD found_VBN in_IN both_DT copies_NNS of_IN the_DT 16S_JJ rRNA_NN genes_NNS ._SENT TABLE_NN 2_CD |_SYM MICs_NN for_IN various_JJ H._NP pylori_NNS strains_NNS as_RB determined_VBN by_IN E-test_NN Until_IN recently_RB tetracycline_NN resistance_NN in_IN H._NP pylori_NNS was_VBD rare_JJ ,_, but_CC in_IN the_DT last_JJ 2_CD years_NNS ,_, several_JJ TetrH_NP ._SENT pylori_NNS strains_NNS have_VBP been_VBN isolated_VBN (_( ,_, ,_, ;_: Midolo_NP et_FW al._FW ,_, letter_NN )_) ._SENT These_DT Tetr_NP clinical_JJ isolates_NNS showed_VBD ,_, besides_IN tetracycline_NN resistance_NN ,_, cross-resistance_NN to_TO metronidazole_NN (_( ,_, ,_, ;_: Midolo_NP et_FW al._FW ,_, letter_NN )_) ._SENT The_DT tetracycline_NN resistance_NN present_JJ in_IN these_DT strains_NNS was_VBD always_RB transferred_VBN together_RB with_IN metronidazole_NN resistance_NN to_TO a_DT Tets_NP strain_NN ._SENT In_IN these_DT Tetr_NP strains_VBZ it_PP is_VBZ not_RB clear_JJ whether_IN the_DT tetracycline_NN resistance_NN is_VBZ caused_VBN by_IN a_DT known_VBN metronidazole_NN resistance_NN mechanism_NN ,_, a_DT multidrug_NN resistance_NN mechanism_NN ,_, or_CC an_DT unknown_JJ tetracycline_NN resistance_NN mechanism_NN ._SENT In_IN our_PP$ TetrH_NP ._SENT pylori_NNS strain_VBP 181_CD ,_, no_DT cross-resistance_NN was_VBD found_VBN against_IN metronidazole_NN ,_, which_WDT indicated_VBD that_IN the_DT molecular_JJ mechanism_NN of_IN tetracycline_NN resistance_NN in_IN strain_NN 181_CD could_MD be_VB different_JJ from_IN that_DT of_IN these_DT earlier-described_JJ TetrH_NP ._SENT pylori_NNS strains_NNS ._SENT In_IN H._NP pylori_NNS strain_VBP 181_CD resistance_NN to_TO tetracycline_NN is_VBZ mediated_VBN by_IN a_DT single_JJ triple-base-pair_NN substitution_NN ,_, AGA926-928_NP ->_NP TTC_NP (_( corresponding_JJ to_TO bp_NN 965_CD to_TO 967_CD of_IN Escherichia_NP coli_NNS 16S_NP rRNA_NP )_) ,_, present_JJ in_IN both_DT copies_NNS of_IN the_DT 16S_JJ rRNA_NN gene_NN ._SENT Tetracycline_NN has_VBZ one_CD primary_JJ and_CC multiple_JJ secondary_JJ binding_JJ sites_NNS within_IN the_DT 30S_JJ ribosomal_JJ subunit_NN ._SENT In_IN the_DT primary_JJ binding_JJ site_NN ,_, tetracycline_NN binds_NNS exclusively_RB to_TO the_DT 3'-major_JJ domain_NN of_IN the_DT 16S_JJ rRNA_NN ._SENT The_DT primary_JJ binding_JJ pocket_NN for_IN tetracycline_NN is_VBZ formed_VBN by_IN the_DT 16S_JJ rRNA_NN residues_NNS 1054_CD to_TO 1056_CD and_CC 1196_CD to_TO 1200_CD of_IN helix_NN 34_CD and_CC residues_NNS 964_CD to_TO 967_CD of_IN helix_NN 31_CD (_( numbers_NNS corresponding_JJ to_TO E._NP coli_NNS 16S_JJ rRNA_NN )_) ._SENT The_DT residues_NNS 1054_CD and_CC 1196_CD interact_VBP primarily_RB with_IN tetracycline_NN through_IN hydrophobic_JJ interactions_NNS ,_, but_CC the_DT majority_NN of_IN the_DT interaction_NN with_IN the_DT drug_NN is_VBZ made_VBN through_IN hydrogen_NN bonds_NNS and_CC salt_NN bridges_NNS between_IN tetracycline_NN and_CC the_DT 16S_JJ rRNA_NN residues_NNS ._SENT In_IN the_DT TetrH_NP ._SENT pylori_NNS strain_VBP 181_CD ,_, the_DT triple-base-pair_NN substitution_NN AGA926-928->TTC_NP is_VBZ located_VBN right_RB in_IN the_DT primary_JJ binding_JJ site_NN of_IN tetracycline_NN ._SENT Mutations_NNS in_IN this_DT primary_JJ binding_JJ site_NN are_VBP likely_JJ to_TO affect_VB the_DT affinity_NN of_IN the_DT drug-ribosome_NN interaction_NN and_CC thus_RB the_DT efficacy_NN of_IN tetracycline_NN as_IN a_DT translational_JJ inhibitor_NN ._SENT In_IN E._NP coli_NNS ,_, the_DT nucleotides_NNS G966_NP and_CC C967_NP are_VBP located_VBN not_RB only_RB in_IN the_DT primary_JJ binding_JJ site_NN of_IN tetracycline_NN but_CC also_RB in_IN a_DT functional_JJ region_NN of_IN the_DT ribosome_NN ,_, the_DT P_NN site_NN ._SENT Mutations_NNS in_IN this_DT region_NN may_MD affect_VB protein_NN synthesis_NN ,_, either_CC by_IN a_DT change_NN in_IN binding_VBG of_IN tRNA_NN to_TO the_DT P_NN site_NN itself_PP or_CC by_IN blocking_VBG the_DT conformational_JJ change_NN needed_VBN for_IN the_DT tRNA_NN binding_VBG to_TO the_DT A_NP site_NN ._SENT In_IN H._NP pylori_NNS strain_VBP 181_CD and_CC the_DT Tetr_NP transformants_NNS of_IN strain_NN 26695_CD ,_, the_DT triple-base-pair_NN substitution_NN AGA926-928->TTC_NP had_VBD no_DT effect_NN on_IN the_DT growth_NN rate_NN of_IN the_DT bacterium_NN in_IN the_DT presence_NN or_CC absence_NN of_IN tetracycline_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Similar_JJ observations_NNS were_VBD found_VBN with_IN E._NP coli_NNS after_IN the_DT substitution_NN of_IN the_DT nucleotides_NNS G966_NP and_CC C967_NP ._SENT This_DT suggests_VBZ that_IN the_DT triple-base-pair_NN substitution_NN AGA926-928->TTC_NP present_NN in_IN H._NP pylori_NNS strain_NN 181_CD does_VBZ not_RB seem_VB to_TO affect_VB protein_NN synthesis_NN of_IN H._NP pylori_NNS ._SENT During_IN revision_NN of_IN this_DT work_NN ,_, Trieber_NP and_CC Taylor_NP reported_VBD that_IN an_DT identical_JJ AGA->TTC_NP substitution_NN mediates_VBZ tetracycline_NN resistance_NN in_IN an_DT unrelated_JJ H._NP pylori_NNS strain_NN (_( Midolo_NP et_FW al._FW ,_, letter_NN )_) ._SENT None_NN of_IN the_DT other_JJ mutations_NNS found_VBN in_IN their_PP$ isolates_NNS (_( G332->A_NP ,_, and_CC the_DT deletions_NNS G733_NP and_CC G903_NP [_SYM numbering_VBG according_VBG to_TO 16S_JJ rrnA_NN of_IN H._NP pylori_NNS strain_VBP 26695_CD ]_SYM )_) play_VB a_DT role_NN in_IN tetracycline_NN resistance_NN of_IN the_DT Tetr_NP strain_NN 181_CD ,_, since_IN these_DT mutations_NNS were_VBD not_RB present_JJ in_IN our_PP$ Tetr_NP isolate_NN ._SENT The_DT differences_NNS found_VBN in_IN the_DT MIC_NN of_IN tetracycline_NN for_IN the_DT triple-base-pair_JJ substitution_NN mutant_NN between_IN the_DT study_NN of_IN Trieber_NP and_CC ours_PP are_VBP only_RB due_JJ to_TO the_DT methods_NNS used_VBN for_IN the_DT determination_NN of_IN the_DT MIC_JJ (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT finding_NN that_IN in_IN two_CD unrelated_JJ H._NP pylori_NNS strains_VBZ the_DT exact_JJ same_JJ mutation_NN is_VBZ responsible_JJ for_IN tetracycline_NN resistance_NN opens_VBZ possibilities_NNS for_IN the_DT development_NN of_IN molecular_JJ screening_NN tests_NNS for_IN tetracycline_NN resistance_NN in_IN H._NP pylori_NNS ._SENT FIG._NN 3_CD ._SENT |_SYM Schematic_NP representation_NN of_IN the_DT primary_JJ binding_JJ site_NN of_IN tetracycline_NN ,_, based_VBN on_IN the_DT 16S_JJ rRNA_NN structure_NN of_IN Thermus_NP thermophilus_NN proposed_VBN by_IN Wimberly_NP et_FW al._FW Schematic_NP representation_NN of_IN the_DT primary_JJ binding_JJ site_NN of_IN tetracycline_NN ,_, based_VBN on_IN the_DT 16S_JJ rRNA_NN structure_NN of_IN Thermus_NP thermophilus_NN proposed_VBN by_IN Wimberly_NP et_FW al._FW ._SENT The_DT primary_JJ binding_JJ pocket_NN for_IN tetracycline_NN is_VBZ formed_VBN by_IN the_DT 16S_JJ rRNA_NN residues_NNS 1054_CD to_TO 1056_CD (_( box_NN A_NP )_) and_CC residues_NNS 1196_CD to_TO 1200_CD (_( box_NN B_NN )_) of_IN helix_NN 34_CD and_CC residues_NNS 964_CD to_TO 967_CD of_IN helix_NN 31_CD (_( box_NN C_NP )_) ._SENT The_DT interactions_NNS between_IN tetracycline_NN and_CC this_DT pocket_NN are_VBP formed_VBN by_IN hydrophobic_JJ interactions_NNS ,_, hydrogen_NN bonds_NNS ,_, and_CC salt_NN bridges_NNS ._SENT The_DT triple-base-pair_NN substitution_NN AGA926-928->TTC_NP (_( corresponding_JJ to_TO bp_NN 965_CD to_TO 967_CD of_IN E._NP coli_NNS 16S_JJ rRNA_NN )_) is_VBZ located_VBN in_IN box_NN C_NP and_CC is_VBZ indicated_VBN by_IN asterisks_NNS ._SENT 